tbuckley/cabot-search huggingface dataset:
Abstract 217: Increased Oxidation of Amplex Red in Post-Cardiac Arrest Human and Rat Plasma Can Be Utilized as a Potential Marker of Injury Severity
Authors: Muhammad Shoaib, Ann Iverson, Tai Yin, Lance B Becker, Junhwan KIM
Journal: Circulation (2019)

Introduction: Cardiac arrest (CA), an unexpected loss of appropriate electrical signaling in the heart, leads to a loss of blood circulation and decreased oxygen perfusion. Ischemia results in the generation of hydrogen peroxide and other reactive oxygen species (ROS), thereby causing damage to tissues. Currently, there are no available biomarkers to elucidate the severity of ischemic damage. Therefore, oxidation of the Amplex Red (AR) assay by ROS into its fluorescent product, resorufin, may be used as a marker to determine injury severity. Methods: Plasma isolated from human CA patients from North Shore University Hospital was obtained to determine ROS generation. A commercially available Amplex Red assay kit was used to measure the amount of resorufin produced after oxidation due to hydrogen peroxide, peroxynitrite, and other ROS. To verify our human findings, we arbitrarily assigned adult male Sprague-Dawley rats into three groups (control, 10 min cardiac arrest, and 20 min cardiac arrest) using our reliable asphyxia-induced cardiac arrest model. Results: Despite human variations, our data on human CA patients showed an increased amount of AR oxidation as a result of ischemia. Our 10 min CA rat experimental model verified that Amplex Red is capable of detecting hydrogen peroxide and peroxynitrite formation after ischemia. Rats with 20 mins of ischemia time also produced resorufin, confirming that ischemia induces AR oxidation. Removing horseradish peroxidase and adding catalase controls for hydrogen peroxide and peroxynitrite, which should decrease AR oxidation; however, we observed an increase in AR oxidation. Therefore, we added phenylmethyl sulfonyl acid (PMSF), an inhibitor of carboxylesterase, an enzyme also capable of oxidizing Amplex Red, which resulted in decreased AR oxidation. Conclusion: By accounting for peroxide and peroxynitrite species, the increase in Amplex Red oxidation in the plasma of cardiac arrest human patients and rats can be attributed to carboxylesterase activity. Our data corroborates the various mechanisms of AR oxidation in the setting of ischemia-reperfusion allowing the Amplex Red assay to be utilized as a potential tool for assessing the degree of ischemic damage resulting from cardiac arrest.
Financial toxicity in lung cancer: an assessment of magnitude, perception, and impact on quality of life
Authors: S.Z. Hazell, W. Fu, C. Hu, K.R. Voong, B. Lee, V. Peterson, J.L. Feliciano, L.H. Nicholas, T.R. McNutt, P. Han, R.K. Hales
Journal: Annals of Oncology (2020)
Pharmacodynamic (PD) – Pharmacokinetic (PK) Study of Ficlatuzumab(F), A Monoclonal Antibody (MAB) Directed to the Hepatocyte Growth Factor (HGF), in Patients (PTS) with Advanced Solid Tumors who have Liver Metastases (METS)
Authors: E. Elez, J. Tabernero, L. Prudkin, S. Agarwal, M. Han, M. Credi, W. Yin, N. Kuriyama, J. Baselga
Journal: Annals of Oncology (2012)
Retinal Pigment Epithelium Replacement Therapy for Age-Related Macular Degeneration: Are We There Yet?
Authors: Ruchi Sharma, Devika Bose, Arvydas Maminishkis, Kapil Bharti
Journal: The Annual Review of Pharmacology and Toxicology (2020)

Pluripotent stem cells (PSCs) are a potential replacement tissue source for degenerative diseases. Age-related macular degeneration (AMD) is a blinding disease triggered by degeneration of the retinal pigment epithelium (RPE), a monolayer tissue that functionally supports retinal photoreceptors. Recently published clinical and preclinical studies have tested PSC-derived RPE as a potential treatment for AMD. Multiple approaches have been used to manufacture RPE cells, to validate them functionally, to confirm their safety profile, and to deliver them to patients either as suspension or as a monolayer patch. Since most of these studies are at an early regulatory approval stage, the primary outcome has been to determine the safety of RPE transplants in patients. However, preliminary signs of efficacy were observed in a few patients. Here, we review the current progress in the PSC-derived RPE transplantation field and provide a comparative assessment of various approaches under development as potential therapeutics for AMD.
Phototherapy: Acid‐Triggered Charge‐Convertible Graphene‐Based All‐in‐One Nanocomplex for Enhanced Genetic Phototherapy of Triple‐Negative Breast Cancer (Adv. Healthcare Mater. 1/2020)
Authors: Chunhui Wu, Yuan Tian, Yingxue Zhang, Jiming Xu, Yikun Wang, Xiaotian Guan, Tingting Li, Hong Yang, Shun Li, Xiang Qin, Yiyao Liu
Journal: Advanced Healthcare Materials (2020)

In article number 1901187 by Chunhui Wu, Yiyao Liu, and co-workers, an acid-triggered charge-reversible graphene-based all-in-one nanocomplex is developed for simultaneous and controlled delivery of photosensitizer and oligonucleotide inhibitor of miR-21. It exhibits prominent therapeutic advantages of gene-photo combination treatment of cancer by antagonizing the miR-21 signal axile by laser irradiation.
Association of marked thrombocytopenia at postoperative day 1 with incidence of liver dysfunction, morbidity, and mortality in metastatic colorectal cancer patients undergoing liver resection.
Authors: Thomas Gruenberger, Beata Perisanidis, Dietmar Tamandl, Stefan Stremitzer, Christine Brostjan, Birgit Gruenberger, Patrick Starlinger
Journal: Journal of Clinical Oncology (2012)

e14095 Background: After major liver resection, the most significant factor determining postoperative morbidity and mortality is the ability of the remnant liver to regenerate. Liver regeneration is a tightly regulated process involving various different growth factors. Recently, platelets have been shown to play a pivotal role in liver regeneration after partial hepatectomy. Methods: Patients treated with liver resection for metastatic colorectal cancer (mCRC) between January 2000 and December 2010 were eligible. Liver dysfunction (LD) was defined as bilirubin &gt; 5 mg/dL or prothrombin time &lt;50% within the first postoperative week. The association of marked immediate postoperative thrombocytopenia with LD, morbidity and mortality was analyzed. Results: 518 patients with mCRC were treated for liver metastasis, of whom 476 underwent liver resection. 67.9% of these had received preoperative CTx. 20.1% of all patients developed LD. Postoperative complications occurred in 39%. 7 patients died within 90 days after liver resection (1.5%). Postoperative platelets &lt; 100 x 10 3 /ml on the first postoperative day were the only liver function parameter predicting postoperative LD in multivariate analyses (p = 0.015). Furthermore, reduced platelets were significantly associated with increased morbidity (p = 0.014) and mortality (platelets &lt; 100 x 10 3 /ml – 4.1%, platelets &gt; 100 x 10 3 /ml – 1.5%, p = n.s.). Conclusions: Platelets &lt; 100 x 10 3 /ml on the first postoperative day seem to be an early marker to predict postoperative LD, increased morbidity and mortality in patients after liver resection. Using this cut-off, it might be possible to identify patients at high risk for developing postoperative LD and complications already on the first day after liver resection. Furthermore, this data suggests a pivotal role of platelets in hepatic regeneration.
Sensitization to grass pollen allergen molecules in a birth cohort—natural Phl p 4 as an early indicator of grass pollen allergy
Authors: Marit Westman, Karin Åberg, Danijela Apostolovic, Christian Lupinek, Pia Gattinger, Irene Mittermann, Niklas Andersson, Erik Melén, Anna Bergström, Josep M. Antó, Jean Bousquet, Rudolf Valenta, Magnus Wickman, Marianne van Hage
Journal: Journal of Allergy and Clinical Immunology (2020)
Randomized Phase II Study of Adjuvant Chemotherapy with S-1 Versus CDDP + S-1 in Resected Stage II-IIIA Non-Small-Cell Lung Cancer (WJOG4107)
Authors: H. Yoshioka, Y. Iwamoto, S. Ito, T. Yamanaka, H. Tada, M. Yoshimura, I. Okamoto, I. Yoshino, K. Nakagawa, Y. Nakanishi
Journal: Annals of Oncology (2012)
Mortality in children and adolescents following presentation to hospital after non-fatal self-harm in the Multicentre Study of Self-harm: a prospective observational cohort study
Authors: Keith Hawton, Liz Bale, Fiona Brand, Ellen Townsend, Jennifer Ness, Keith Waters, Caroline Clements, Nav Kapur, Galit Geulayov
Journal: The Lancet Child & Adolescent Health (2020)
Prognostic impact of baseline tumour immune infiltrate on disease-free survival in patients with completely resected, BRAFv600 mutation–positive melanoma receiving adjuvant vemurafenib
Authors: P.A. Ascierto, K.D. Lewis, A.M. Di Giacomo, L. Demidov, M. Mandalà, I. Bondarenko, C. Herbert, A. Mackiewicz, P. Rutkowski, A. Guminski, B. Simmons, C. Ye, G. Hooper, M.J. Wongchenko, G.R. Goodman, Y. Yan, D. Schadendorf
Journal: Annals of Oncology (2020)

We conducted a retrospective exploratory analysis to evaluate the effects of baseline tumour immune infiltrate on disease-free survival (DFS) outcomes in patients with fully resected stage IIC-IIIC melanoma receiving adjuvant vemurafenib monotherapy or placebo in the BRIM8 study.BRIM8 was a phase III, international, double-blind, randomised, placebo-controlled study. Eligible patients with BRAFV600 mutation-positive, completely resected melanoma were randomly assigned to oral vemurafenib (960 mg twice daily) or matching placebo for 52 weeks. The primary end point was DFS. The association of CD8+ T-cell infiltration and programmed death ligand 1 (PD-L1) expression with DFS, as measured by immunohistochemistry, was explored retrospectively.Four hundred ninety-eight patients were randomly assigned to receive adjuvant vemurafenib (n = 250) or placebo (n = 248); tumour samples were available for biomarker analysis for approximately 60% of patients. In the pooled biomarker population, placebo-treated patients with <1% CD8+ T cells in the tumour centre had shorter median DFS than those with ≥1% CD8+ T cells (7.7 versus 47.8 months). DFS benefit from vemurafenib versus placebo was greater in patients with <1% CD8+ T cells [hazard ratio (HR) 0.56; 95% confidence interval (CI) 0.34-0.92) than in patients with ≥1% CD8+ T cells (HR 0.77; 95% CI 0.48-1.22). Likewise, median DFS was shorter among placebo-treated patients with <5% versus ≥5% PD-L1+ immune cells (IC) in the tumour (7.2 versus 47.8 months). A greater DFS benefit with vemurafenib versus placebo was observed in patients with <5% PD-L1+IC (HR 0.36; 95% CI 0.24-0.56) than in patients with ≥5% PD-L1+IC (HR 0.99; 95% CI 0.58-1.69).The presence of CD8+ T cells and PD-L1+IC are favourable prognostic factors for DFS. Treatment with adjuvant vemurafenib may overcome the poor DFS prognosis associated with low CD8+ T-cell count or PD-L1 expression. CLINICALTRIALS.NCT01667419.
Blood Vessels with Different Characteristics have Distinct Impact on Survival of Glioblastoma Multiforme Patients
Authors: M. Kase, A. Minajeva, K. Niinepuu, S. Kase, A. Adamson, M. Saretok, M. Vardja, T. Asser, J. Jaal
Journal: Annals of Oncology (2012)
Integrating tumor hypoxic stress in novel and more adaptable strategies for cancer immunotherapy
Authors: Raefa Abou Khouzam, Hassan Venkatesh Goutham, Rania Faouzi Zaarour, Ali N Chamseddine, Amirtharaj Francis, Stéphanie Buart, Stéphane Terry, Salem Chouaib
Journal: Seminars in Cancer Biology (2020)
Predictors of sudden cardiac death in high‐risk patients following a myocardial infarction
Authors: Kieran F. Docherty, João Pedro Ferreira, Abhinav Sharma, Nicolas Girerd, John Gregson, Kevin Duarte, Mark C. Petrie, Pardeep S. Jhund, Kenneth Dickstein, Marc A. Pfeffer, Bertram Pitt, Patrick Rossignol, Faiez Zannad, John J.V. McMurray
Journal: European Journal of Heart Failure (2020)
Beings in the moment
Authors: Mark A. Elliott
Journal: Behavioral and Brain Sciences (2019)

Abstract Hoerl &amp; McCormack's theory defines temporal behavior from an awareness of time, but lacks one critical element: the impact of “psychological presence” in the “moment now.” Central to experience of temporal non-stationarity: “Nowness” links future with past in the context of time flow. Does this differ between species? Evidence suggests not: Different temporal experiences between species requires greater critical evaluation.
Multicentric Phase II Randomized Trial Comparing Chemoradiation (CHRT) with 5-Fluorouracil, Cisplatin (CDDP) and 50 GY versus Chemotherapy Alone (CH) with Gemcitabine (G) Plus Oxaliplatin (O) for Locally advanced Biliary Tract Cancer (FFCD9902)
Authors: J.M. Phelip, V. Vendrely, J. Jouve, F. Subtil, M. Gasmi, P. Michel, D. Smith, J. Seitz, L. Bedenne, B. Chauffert
Journal: Annals of Oncology (2012)
Is there a place for crizotinib in c-MET alterations? A case of efficacy in ALK positive NSCLC patient with secondary c-MET amplification
Authors: M. Mazzotta, M. Filetti, A. Rossi, M. Roberto, M. Occhipinti, A. Pernazza, A. Di Napoli, S. Scarpino, A. Vecchione, R. Giusti, P. Marchetti
Journal: Annals of Oncology (2020)
Japanese Cohort Study of First Line Chemotherapy (CT) for Metastatic Colorectal Cancer (MCRC) Containing Fluoropyrimidine, Oxaliplatin and Bevacizumab: Emerald Study, First Report
Authors: K. Taku, K. Ohata, K. Yamazaki, G. Nishikawa, M. Watanabe, S. Sato, T. Oshima, H. Hirano, T. Amano, Y. Ohashi
Journal: Annals of Oncology (2012)
Pancreatic Ductal Adenocarcinoma: A Homogeneous Morphologically but Molecularly Heterogeneous Tumor. IMPLICATIONS for its Management
Authors: L. Faloppi, A. Mandolesi, M. Scartozzi, C. Loretelli, M. Bianconi, A. Bittoni, R. Giampieri, M. Del Prete, I. Bearzi, S. Cascinu
Journal: Annals of Oncology (2012)
Machine intelligence in peptide therapeutics: A next‐generation tool for rapid disease screening
Authors: Shaherin Basith, Balachandran Manavalan, Tae Hwan Shin, Gwang Lee
Journal: Medicinal Research Reviews (2020)

Discovery and development of biopeptides are time-consuming, laborious, and dependent on various factors. Data-driven computational methods, especially machine learning (ML) approach, can rapidly and efficiently predict the utility of therapeutic peptides. ML methods offer an array of tools that can accelerate and enhance decision making and discovery for well-defined queries with ample and sophisticated data quality. Various ML approaches, such as support vector machines, random forest, extremely randomized tree, and more recently deep learning methods, are useful in peptide-based drug discovery. These approaches leverage the peptide data sets, created via high-throughput sequencing and computational methods, and enable the prediction of functional peptides with increased levels of accuracy. The use of ML approaches in the development of peptide-based therapeutics is relatively recent; however, these techniques are already revolutionizing protein research by unraveling their novel therapeutic peptide functions. In this review, we discuss several ML-based state-of-the-art peptide-prediction tools and compare these methods in terms of their algorithms, feature encodings, prediction scores, evaluation methodologies, and software utilities. We also assessed the prediction performance of these methods using well-constructed independent data sets. In addition, we discuss the common pitfalls and challenges of using ML approaches for peptide therapeutics. Overall, we show that using ML models in peptide research can streamline the development of targeted peptide therapies.
S100A11/ANXA2 belongs to a tumour suppressor/oncogene network deregulated early with steatosis and involved in inflammation and hepatocellular carcinoma development
Authors: Cyril Sobolewski, Daniel Abegg, Flavien Berthou, Dobrochna Dolicka, Nicolas Calo, Christine Sempoux, Margot Fournier, Christine Maeder, Anne-Sophie Ay, Pierre-Alain Clavien, Bostjan Humar, Jean-François Dufour, Alexander Adibekian, Michelangelo Foti
Journal: Gut (2020)

Objective Hepatocellular carcinoma (HCC) development occurs with non-alcoholic fatty liver disease (NAFLD) in the absence of cirrhosis and with an increasing incidence due to the obesity pandemic. Mutations of tumour suppressor (TS) genes and oncogenes (ONC) have been widely characterised in HCC. However, mounting evidence indicates that non-genomic alterations of TS/ONC occur early with NAFLD, thereby potentially promoting hepatocarcinogenesis in an inflammatory/fibrotic context. The aim of this study was to identify and characterise these alterations. Design The proteome of steatotic liver tissues from mice spontaneously developing HCC was analysed. Alterations of TSs/ONCs were further investigated in various mouse models of NAFLD/HCC and in human samples. The inflammatory, fibrogenic and oncogenic functions of S100A11 were assessed through in vivo, in vitro and ex-vivo analyses. Results A whole set of TSs/ONCs, respectively, downregulated or upregulated was uncovered in mice and human with NAFLD. Alterations of these TSs/ONCs were preserved or even exacerbated in HCC. Among them, overexpression of S100A11 was associated with high-grade HCC and poor prognosis. S100A11 downregulation in vivo significantly restrains the development of inflammation and fibrosis in mice fed a choline/methionine-deficient diet. Finally, in vitro and ex-vivo analyses revealed that S100A11 is a marker of hepatocyte de-differentiation, secreted by cancer cells, and promoting cell proliferation and migration. Conclusion Cellular stress associated with NAFLD triggers non-genomic alterations of a whole network of TSs/ONCs fostering hepatocarcinogenesis. Among those, overexpression of the oncogenic factor S100A11 promotes inflammation/fibrosis in vivo and is significantly associated with high-grade HCC with poor prognosis.
Biomarker (BM) Results from the Phase III Averel Trial of 1st-Line Bevacizumab (BV), Trastuzumab (H) + Docetaxel (T) for HER2-Positive Locally Recurrent/Metastatic Breast Cancer (LR/MBC)
Authors: L. Gianni, A. Chan, M. Mansutti, X. Pivot, R. Greil, L. Provencher, S. Prot, N. Moore, S.J. Scherer, C. Pallaud
Journal: Annals of Oncology (2012)
Clinical Relevance of Hormone Receptors, Ki67 and Her-2 Status as Biomarkers Surrogate for Breast Cancer Molecular Subtypes: A Retrospective Analysis of Disease Free Survival in Patients with T1 N0/N+ Breast Cancer
Authors: A. Emiliani, A. Iannace, G. Nigita, T. Losanno, G. Manna, E. Franzese, L. Frati
Journal: Annals of Oncology (2012)
Practical guidelines on endoscopic treatment for Crohn's disease strictures: a consensus statement from the Global Interventional Inflammatory Bowel Disease Group
Authors: Bo Shen, Gursimran Kochhar, Udayakumar Navaneethan, Francis A Farraye, David A Schwartz, Marietta Iacucci, Charles N Bernstein, Gerald Dryden, Raymond Cross, David H Bruining, Taku Kobayashi, Martin Lukas, Amandeep Shergill, Martin Bortlik, Nan Lan, Milan Lukas, Shou-Jiang Tang, Paulo Gustavo Kotze, Ravi P Kiran, Parambir S Dulai, Sandra El-Hachem, Nayantara Coelho-Prabhu, Shyam Thakkar, Ren Mao, Guodong Chen, Shengyu Zhang, Begoña González Suárez, Yago Gonzalez Lama, Mark S Silverberg, William J Sandborn
Journal: The Lancet. Gastroenterology & hepatology (2020)
Customized First Line Chemotherapy According to ERCC1 and RRM1 SNPS in Advanced Non-Small-Cell Lung Cancer (NSCLC) Patients: A Phase II Study
Authors: F. Mazzoni, G. Meoni, F.L. Cecere, C. Giuliani, A. Camerini, G. Allegrini, F. Martella, L. Boni, F. Torricelli, F. Di Costanzo
Journal: Annals of Oncology (2012)
Health-related quality of life (HRQOL) in patients with glioblastoma (GBM) and their caregivers in the end-of-life phase: A retrospective study.
Authors: Birgit Flechl, Cornelia Sax, Michael Ackerl, Richard Crevenna, Alexander Gaiger, Mohammad Keilani, Matthias Preusser, Karin Dieckmann, Georg Widhalm, Stefan Oberndorfer, Bernadette Calabek, Jaap Reijneveld, Eefje Sizoo, Christine Marosi
Journal: Journal of Clinical Oncology (2012)

2071 Background: Glioblastoma multiforme (GBM) still harbours an inevitably fatal prognosis. The specially course of this disease poses unique challenges in care provision to the relatives. We still lack data about the end-of-life phase of GBM patients to improve counseling and supporting GBM patients and their proxies. Methods: In this retrospecitve study we included 52 caregivers of deceased GBM patients treated in two hospitals in Vienna, Austria. We used a specially developed questionnaire by the Medical University of Amsterdam to explore and document the last three months of living of GBM patients. Results: Most of the included caregivers were the partners of the patients (88%) and two thirds were female. The most common symptom in GBM patients was fatigue (87%), followed by reduced consciousness (81%) and aphasia (77%). 22% of the patients were bedbound during their last three months increasing to 80% in the last week of life. 30% of the caregivers told that they felt incompletely informed for their task and about the illness of their loved one. They stated the quality of life (QOL) of the patients with 2.2 and their own with 2.8 on a scale of 1 to 7 whereas 7 displays the best possible answer. The majority of the patients (46%) died in hospitals and 38% at home, which was the most often expressed wish for place of death (45%)by patients. Regarding the caregivers’ symptoms, sadness (90%), fear (69%), burnout (60%), less interest in others (54%) and irritation (42%) were the leading ones and did not differ significantly in-between the places of death. Conclusions: The end-of-life phase of GBM patients is different from that of patients dying from other cancers. Most alarmingly, one thirds of their caregivers feels poorly informed. About two thirds of the caregivers fell overstrained and stresses thereby the urgent need for support and dedicated educational programs.
<scp>DNA</scp> Vaccination With Hsp70 Protects Against Systemic Lupus Erythematosus in (<scp>NZB</scp> × <scp>NZW</scp>)F1 Mice
Authors: Aijing Liu, Concetta Ferretti, Fu‐Dong Shi, Irun R. Cohen, Francisco J. Quintana, Antonio La Cava
Journal: Arthritis & Rheumatology (2020)

To address whether a targeted modulation of the abnormal expression of Hsp70 and autoantibodies against this molecule in systemic lupus erythematosus can influence disease.Lupus-prone (NZB × NZW)F1 mice that had been DNA-vaccinated with plasmids encoding Hsp70 and controls were monitored for lupus disease parameters including anti-double stranded DNA (anti-dsDNA) autoantibodies and cytokines using enzyme-linked immunosorbent assay, and for kidney function and pathology. The phenotypic and numerical changes in relevant immune cells were evaluated by flow cytometry, and cell function was assessed.Mice that had been DNA-vaccinated with Hsp70 displayed marked suppression of anti-dsDNA antibody production, reduced renal disease, and antiinflammatory responses that are associated with a significantly extended survival, compared to controls. These protective effects in Hsp70-vaccinated mice were associated with an induction of tolerogenic immune responses and an expansion of functional Treg cells.DNA vaccination with Hsp70 suppresses murine lupus by inducing tolerogenic immune responses and antiinflammatory immune responses associated with reduced disease manifestations and increased mouse survival.
P-0160 Role of Measurement of C-Kit Protein Serum Levels In Monitoring Patients with Gastrointestinal Stromal Tumors (Gist): Preliminary Results
Authors: Vasiliki Kakavetsi-Dimaki, Periklis Apostolopoulos, Andreas Karameris, Antonis Zalonis, Ioannis Koumoutsos, Ilona Dzhabieva, Panagiotis Tsimbouris, Adam Adamopoulos, Irene Zoumboulis-Vafiadis, Georgios Alexandrakis, Spyridon Ladas
Journal: Annals of Oncology (2012)
Randomized Phase II Trial of Carboplatin Combined with Weekly Paclitaxel (CWP) and Docetaxel Alone (D) in Elderly Patients with Advanced Non-Small-Cell Lung Cancer (NSCLC): NJLCG 0801
Authors: A. Inoue, M. Maemondo, S. Sugawara, T. Harada, Y. Minegishi, K. Usui, M. Ando, N. Morikawa, Y. Mori, O. Ishimoto, N. Matsubara, T. Sakakibara, K. Watanabe, A. Gemma, T. Nukiwa
Journal: Annals of Oncology (2012)